Management of retinoblastoma: opportunities and challenges

References

• Abramson DH. (2005). Retinoblastoma in the 20th century: past success and future challenges. The Weisenfeld Lecture. Invest Ophthalmol Vis Sci 46:2684–91
   Web of Science ®Google Scholar
• Aerts I, Rouic LL, Gauthier-villars M, et al. (2006). Retinoblastoma. Orphanet J Rare Dis 31:1–11
   Google Scholar
• Anderson JM, Shive MS. (1997). Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28:5–24
   PubMed Web of Science ®Google Scholar
• Balderrama J, Carlos Leal-Leal A, Alvis-Miranda H, et al. (2013). Intra-arterial chemotherapy for retinoblastoma: a practical review. Rom Neurosurg 20:327–33
   Google Scholar
• Balmer A, Zografos L, Munier F. (2006). Diagnosis and current management of retinoblastoma. Oncogene 38:5341–9
   Web of Science ®Google Scholar
• Barenholz Y. (2012). Doxil® – the first FDA-approved nano-drug: lessons learned. J Control Rel 160:117–34
   PubMed Web of Science ®Google Scholar
• Bishop JO, Madsen EC. (1975). Retinoblastoma: review of current status. Surv Ophthalmol 19:342–66
   PubMedGoogle Scholar
• Boddu HS, Jwala J, Chowdhury MR, Mitra AK. (2010). In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using doxorubicin as a model drug. J Ocul Pharmacol Therap 26:459–68
   PubMed Web of Science ®Google Scholar
• Bourges J, Gautier SE, Delie F, et al. (2003). Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 44:3562–9
   PubMed Web of Science ®Google Scholar
• Chang JW, Yu YS, Kim JY, et al. (2011). The clinical outcomes of proton beam radiation therapy for retinoblastomas that were resistant to chemotherapy and focal treatment. Korean J Ophthalmol 25:387–93
   PubMedGoogle Scholar
• Chearwae W, Wu CP, Chu HY, et al. (2006a). Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1(ABCC1). Cancer Chemother Pharmacol 57:376–88
   PubMed Web of Science ®Google Scholar
• Chearwae W, Wu CP, Chu HY, et al. (2006b). Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther 5:1995–2006
   PubMed Web of Science ®Google Scholar
• Chintagumpala M, Chevez-Barrios P, Paysse EA, et al. (2007). Retinoblastoma. Rev Curr Manage 12:1237–46
   Google Scholar
• Das M, Sahoo SK. (2012). Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One 7:e329202012
   Web of Science ®Google Scholar
• De Jong WH, Borm PJ. (2008). Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 3:133–49
   PubMed Web of Science ®Google Scholar
• Demirci H, Shields CL, Meadows AT, Shields JA. (2005). Long-term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol 123:1525–30
   PubMed Web of Science ®Google Scholar
• Desjardins L, Levy C, Lumbroso L, et al. (2000). Current treatment of retinoblastoma. 153 children treated between 1995 and 1998. J Fr Ophtalmol 23:475–81
   PubMed Web of Science ®Google Scholar
• Dryja TP, Mukai S, Petersen R, et al. (1989). Parental origin of mutations of the RB gene. Nature 339:556–8
   PubMed Web of Science ®Google Scholar
• Engineer C, Parikh J, Raval A. (2011). Review on hydrolytic degradation behavior of biodegradable polymers from controlled drug delivery system. Trends Biomater Artif Organs 25:79–85
   Google Scholar
• Friedman DL, Himelstein B, Shields CL, et al. (2000). Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 18:12–17
   PubMed Web of Science ®Google Scholar
• Friend SH, Bernards R, Rogelj S, et al. (1986). A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643–6
   PubMed Web of Science ®Google Scholar
• Gallud A, Silva AD, Maynadier M, et al. (2013). A functionalized nanoparticles for drug delivery, one- and two-photon photodynamic therapy as a promising treatment of retinoblastoma. J Clin Exp Ophthalmol 4:1000288
   Google Scholar
• Gary-Bobo M, Mir Y, Rouxel C, et al. (2012). Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: drug delivery, one and two-photon photodynamic therapy. Int J Pharm 432:99–104
   PubMed Web of Science ®Google Scholar
• Gombos DS, Chevez-Barrios AP. (2007a). Current treatment and management of retinoblastoma. Curr Oncol Rep 9:453–8
   PubMedGoogle Scholar
• Gombos DS, Hungerford J, Abramson DH, et al. (2007b). Secondary acute myelogenous leukemia in patients with retinoblastoma. Is chemotherapy a factor? Ophthalmology 114:1378–83
   PubMed Web of Science ®Google Scholar
• Hernandez JC, Brady LW, Shields JA, et al. (1996). External beam radiation for retinoblastoma: results, patterns of failure, and a proposal for treatment guidelines. Int J Radiat Oncol Biol Phys 35:125–32
   PubMed Web of Science ®Google Scholar
• Hironaka K, Fujisawa T, Sasaki H, et al. (2011). Fluorescence investigation of the retinal delivery of hydrophilic compounds via liposomal eyedrops. Bio Pharma Bull 34:894–7
   PubMed Web of Science ®Google Scholar
• Hoffman R. (2002). Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. Lancet Oncol 9:546–56
   Web of Science ®Google Scholar
• Hu T, Le Q, Wu Z, Wu W. (2007). Determination of doxorubicin in rabbit ocular tissues and pharmacokinetics after intravitreal injection of a single dose of doxorubicin-loaded poly-beta-hydroxybutyrate microspheres. J Pharm Biomed Anal 43:263–9
   Google Scholar
• Inokuchi Y, Hironaka K, Fujisawa T, et al. (2009). Physicochemical properties affecting retinal drug/coumarin-6 delivery from nanocarrier systems via eyedrop administration. Invest Ophthalmol Vis Sci 51:3162–70
   Google Scholar
• Izak AM, Werner L, Pandey SK, Apple DJ. (2003). Calcification of modern foldable hydrogel intraocular lens designs. Eye 17:393–406
   PubMed Web of Science ®Google Scholar
• Jabr-Milane LS, Van Vlerken LE, Yadav S, Amiji MM. (2008). Multifunctional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 34:592–602
   PubMed Web of Science ®Google Scholar
• Jaidev LR, Bhavsar DV, Sharma U, et al. (2014). Engineered multifunctional nanomaterials for multimodal imaging of retinoblastoma cells in vitro. J Biomater Sci Polym Ed 25:1093–109
   PubMed Web of Science ®Google Scholar
• Johnstone TC, Park GY, Lippard SJ. (2014). Understanding and improving platinum anticancer drugs phenanthriplatin. Anticancer Res 34:471–6
   PubMed Web of Science ®Google Scholar
• Kang SJ, Durairaj C, Kompella UB, et al. (2009). Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol 127:1043–7
   PubMed Web of Science ®Google Scholar
• Karcioglu ZA, al-Mesfer SA, Abboud E, et al. (1997). Workup for metastatic retinoblastoma: a review of 261 patients. Ophthalmology 104:307–12
   PubMed Web of Science ®Google Scholar
• Kharchenko S, Adamowicz J, Wojtkowski M, Drewa T. (2013). Optical coherence tomography diagnostics for onco-urology: review of clinical perspectives. Cent Eur J Urol 66:136–41
   PubMedGoogle Scholar
• Kim JH, Kim JH, Park JA, et al. (2006). Blood–neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol 39:339–45
   PubMedGoogle Scholar
• Kim ES, Durairaj C, Kadam RS, Lee SJ, Mo Y. (2009a). Geroski DH, Kompella UB, Edelhauser HF. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharmaceut res. 26, 1155–61
   Google Scholar
• Kim JH, Kim JH, Kim KW, et al. (2009b). Intravenously administered gold nanoparicles pass through the blood–retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 20:505101
   PubMed Web of Science ®Google Scholar
• Kivelä T. (2009). The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 93:1129–31
   PubMed Web of Science ®Google Scholar
• Knudson AG. (1971). Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–3
   PubMed Web of Science ®Google Scholar
• Lambert MP, Shields C, Meadows AT. (2008). A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 50:223–6
   PubMed Web of Science ®Google Scholar
• Leal-Leal C, Flores-Rojo M, Medina-Sansón A, et al. (2004). A multicentre report from the Mexican RB Group. Br J Ophthalmol 88:1074–7
   PubMed Web of Science ®Google Scholar
• Li Z, Wu X, Li J, et al. (2012). Antitumor activity of celastrol nanoparticles in a xenograft retinoblastoma tumor model. J Nanomed 7:2389–98
   PubMed Web of Science ®Google Scholar
• Lim JI, Wolitz RA, Dowling AH, et al. (1999). Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 127:288–93
   PubMed Web of Science ®Google Scholar
• Meel R, Radhakrishnan V, Bakhshi S. (2012). Current therapy and recent advances in the management of RB. Indian Journal of Medical and Paediatric Oncology 33:80–8
   PubMedGoogle Scholar
• Mitter D, Ullmann R, Muradyan A, et al. (2011). Genotype-phenotype correlations in patients with retinoblastoma and interstitial 13q deletions. Eur J Hum Genet 19:947–58
   PubMed Web of Science ®Google Scholar
• Mohan A, Shridhar N, Sethuraman S, Krishnan UM. (2014). Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma. BioMed Res, Early Online: 1–14. DOI: org/10.1155/2014/424239
   Google Scholar
• Moutushy M, Dilnawaz F, Misra R, et al. (2011). Toxicogenomics of nanoparticulate delivery of etoposide: potential impact on nanotechnology in retinoblastoma therapy. Cancer Nano 2:21–36
   PubMedGoogle Scholar
• Moutushy M, Kandalam M, Rangasamy J, et al. (2013). Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells. Mol Vis 19:1029–38
   PubMedGoogle Scholar
• Moutushy M, Mohanty C, Harila A, et al. (2012). A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs. Mol Vis 18:1361–78
   PubMed Web of Science ®Google Scholar
• Nair A, Thevenot P, Hu W, Tang L. (2008). Nanotechnology in the treatment and detection of intraocular cancers. J Biomed Nanotechnol 4:410–18
   PubMed Web of Science ®Google Scholar
• Nithya S, Jagdeesh Babu S, Baghavathi B, et al. (2014). A strain-promoted alkyne–azide cycloaddition (SPAAC) reaction of a novel EpCAM aptamer–fluorescent conjugate for imaging of cancer cells. Chem Com 50:11810–13
   Google Scholar
• Nounou NM, El-khordagui LK, Khalafallah NA, Khalil SA. (2006). In vitro release of hydrophilic and hydrophobic drugs from liposomal dispersions and gels. Acta Pharma 56:311–24
   PubMedGoogle Scholar
• Oliveira MF, Guimarães PPG, Gomes ADM, et al. (2013). Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market. J Chem Bio 6:7–23
   Google Scholar
• Pandey AN. (2013). Retinoblastoma: an overview. Saudi J Ophthalmol 28:310–15
   Google Scholar
• Parveen S, Sahoo SK. (2010). Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastoma. Cancer Nano 1:47–62
   PubMedGoogle Scholar
• Ramana LN, Sethuraman S, Ranga U, Krishnan UM. (2010). Development of a liposomal nanodelivery system for nevirapine. J Biomed Sci 17:57
   PubMed Web of Science ®Google Scholar
• Ramsubramanian A, Shields CL. (2012). Retinoblastoma. New Delhi: Jaypee Brothers Medical Publisher
   Google Scholar
• Roarty JD, McLean IW, Zimmerman LE. (1988). Incidence of second neoplasms in patients with bilateral RB. Ophthalmology 95:1583–87
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galindo C, Wilson MW, Chantada G, et al. (2008). Retinoblastoma: one world, one vision. Pediatrics 122:e763
   PubMed Web of Science ®Google Scholar
• Ruben JB, Buckley EJ, Ellis GS, et al. (2008). Red reflex examination in neonates, infants, and children. Pediatrics 122:1401–4
   PubMed Web of Science ®Google Scholar
• Salmaso S, Caliceti P. (2013). Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv 2013:374252
   PubMedGoogle Scholar
• Samuel KH. (2011). Current update on retinoblastoma. Int Ophthalmol Clin 51:77–91
   Google Scholar
• Schmack I, Hubbard GB, Kang SJ, et al. (2006). Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 142:310–15
   PubMed Web of Science ®Google Scholar
• Shane TS, Martin DF. (2003). Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 136:649–54
   PubMed Web of Science ®Google Scholar
• Shang L, Nienhaus K, Nienhaus GU. (2014). Engineered nanoparticles interacting with cells: size matters. J Nanobiotechnol 12:5
   PubMed Web of Science ®Google Scholar
• Shields CL, Mashayekhi A, Au AK, et al. (2006). The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 113:2276–80
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA. (2010a). Review Intra-arterial chemotherapy for retinoblastoma: the beginning of a long journey. Clin Exp Ophthalmol 21:638–43
   Google Scholar
• Shields CL, Shields JA. (2010b). Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra- arterial chemotherapy. Curr Opin Ophthalmol 21:203–12
   PubMed Web of Science ®Google Scholar
• Short BG. (2008). Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol 36:49–62
   PubMed Web of Science ®Google Scholar
• Smith EV, Gragoudas ES, Koloday NH, D’Amic DJ. (1990). Magnetic resonance imaging: an emerging technique for the diagnosis of ocular disorders. Int Ophthalmol 14:119–24
   PubMed Web of Science ®Google Scholar
• Sussman DA, Escalona-Benz E, Benz MS, et al. (2003). Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. Arch Ophthalmol 121:979–84
   PubMed Web of Science ®Google Scholar
• Tiwari G, Tiwari R, Sriwastawa B, et al. (2012). Drug delivery systems: an updated review. Int J Pharm Investig 2:2–11
   PubMedGoogle Scholar
• Van Quill KR, O'Brien JM. (2003). The role of the retinoblastoma protein in health, malignancy, and the pathogenesis of RB. In: Albert DM, Polans A, eds. Ocular oncology. New York: Marcel Dekker, Inc., 103–28
   Google Scholar
• Winkler BS. (1981). Glycolytic and oxidative metabolism in relation to retinal function. J Gen Physiol 77:667–92
   PubMed Web of Science ®Google Scholar
• Wong FL, Boice JD Jr, Abramson DH, et al. (1997). Cancer incidence after retinoblastoma radiation dose and sarcoma risk. J Am Med Assoc 278:1262–7
   PubMed Web of Science ®Google Scholar
• Yamane T, Kaneko A, Mohri M. (2004). The technique of ophthalmic arterial infusion therapy for patients with intraocular retino- blastoma. Int J Clin Oncol 9:69–73
   PubMedGoogle Scholar
• Yu DY, Cringle SJ. (2001). Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. Progr Retina Eye Res 20:175–208
   PubMed Web of Science ®Google Scholar
• Zhu XP, Dunn JM, Phillips RA, et al. (1989). Preferential germline mutation of the paternal allele in retinoblastoma. Nature 340:312–13
   PubMed Web of Science ®Google Scholar